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ABSTRACT  8	  
 9	  
Virtual screening of a drug database identified Carvedilol, Loratadine, Nefazodone 10	  
and Astemizole as PAR2 antagonists, after ligand docking and molecular dynamics 11	  
simulations using a PAR2 homology model and a putative binding mode of a known 12	  
PAR2 ligand. The drugs demonstrated competitive binding and antagonism of 13	  
calcium mobilization and ERK1/2 phosphorylation in CHO-hPAR2 transfected cells, 14	  
while inhibiting IL-6 secretion in PAR2 expressing MDA-MB-231 breast cancer 15	  
cells. This research highlights opportunities for GPCR hit-finding from FDA-16	  
approved drugs. 17	  
 18	  
  19	  
	   2	  
INTRODUCTION 1	  
 2	  
Drug discovery via traditional high-throughput compound screening usually 3	  
furnishes small molecule ligands with modest affinities at low hit rates, with 4	  
considerable subsequent efforts needed for hit-to-lead development and adequate 5	  
profiling for selectivity, toxicity, pharmacokinetics, pharmacodynamics, and 6	  
formulation/delivery. In the last decade, only 0.01% of new drug leads were selected 7	  
for clinical trials1, representing a poor return on medicinal chemistry investment. An 8	  
alternative approach gaining favor in drug discovery is the repurposing of FDA-9	  
approved drugs for new uses, facilitating faster and cheaper progression to the clinic.2 10	  
There have been several examples of successful drug repurposing3-5 and there are 11	  
many examples of drugs approved by the US Food and Drug Administration that 12	  
show promising activities against multiple targets.6  13	  
Protease activated receptor 2 (PAR2) is a unique GPCR where there is no 14	  
known endogenous ligand. Instead, PAR2 is activated by proteases.7-9 Its extracellular 15	  
N-terminus is cleaved predominately by trypsin-like serine proteases to reveal a 16	  
‘neoepitope’ called the tethered ligand (TL), (e.g. SLIGKV, human; SLIGRL, 17	  
murine), which binds intramolecularly and activates PAR2 at an unknown site.10,11 18	  
Studies have shown that PAR2 activation is associated with metabolism, 19	  
inflammation, pain, proliferation, metastasis, angiogenesis, and many cancers 20	  
including pancreatic, colon, breast, prostate and stomach.12 Modulation of PAR2 21	  
represents a potential therapeutic strategy for treating many diseases. Our group 22	  
developed small, serum stable, non-peptidic agonists (e.g. GB110, EC50 ~200 nM, 23	  
Ca2+, HT29 cells)13 and antagonists (e.g. GB88, IC50 1-10 µM, Ca2+)14 that were 24	  
effective in modulating PAR2 in a variety of human cell lines. GB88 has shown 25	  
	   3	  
therapeutic benefits in both in vitro and in vivo models of diseases15-17 and stimulated 1	  
our interest in the development of small molecule modulators of human PAR2. 2	  
GPCRs are notorious for adopting multiple conformations, representing 3	  
different active and inactive states that influence pharmacology. Studies have 4	  
supported successful structural modeling of aminergic GPCRs, but historically there 5	  
have been more difficulties in modeling the peptidergic GPCRs.18 Several successful 6	  
studies have reported virtual screening campaigns using homology structural models 7	  
of GPCRs.19 The number of studies seeking to repurpose drugs via computational 8	  
approaches has steadily increased.6 GPCRs in particular are often associated with 9	  
multiple therapeutic areas, so GPCR ligands potentially represent good candidates for 10	  
rational repurposing of drugs.20 11	  
Proof-of-principle is demonstrated here for the application of computer 12	  
assisted molecular modeling, in combination with in vitro assays, to the mining of a 13	  
database containing 1216 FDA approved drugs for modulating the function of a 14	  
GPCR known as PAR2. From 150 virtual hits, 8 were selected for bioassay and 4 of 15	  
these were inhibitors of PAR2, a hit rate that should encourage future applications of 16	  
the methodology to other GPCRs. 17	  
 18	  
RESULTS AND DISCUSSION 19	  
Previously we used homology models of human PAR2, based on the template 20	  
crystal structure of human nociceptin opioid receptor (ORL-1), to identify putative 21	  
binding modes of PAR2 agonists and to pan for PAR2 antagonists through virtual 22	  
screening of a commercial database (Chembridge).21 In this study, we instead began 23	  
with putative binding modes of the PAR2 antagonist GB8814 and identified an 24	  
ensemble of molecular dynamics (MD) snapshot poses of the docked ligand in the 25	  
	   4	  
PAR2 homology model. Representative conformations were sampled and used for 1	  
prospective docking of various FDA-approved drugs (Figure 1).  2	  
Figure 2A shows a superimposed structure of the homology model of PAR2 with 3	  
the template ORL-1 crystal structure bound by its antagonist (C-24).22 The original 4	  
docking pose of the PAR2 ligand GB88 in the PAR2 homology model suggested that 5	  
the isoxazole ring sits in a pocket near to TM1 and TM7 (Figure 2B). A potential 6	  
hydrogen bond was predicted to form between Tyr82 (residue 1.39) and the nitrogen 7	  
atom of isoxazole. Cyclohexylalanine (Cha) at the 2nd position in GB88 binds 8	  
between TM2 and TM3, near to Phe155 (3.32). Isoleucine at the 3rd position in GB88 9	  
is near to Tyr156 (3.33), Leu307 (6.55), and the spiro[indene-1,4’-piperidine] of 10	  
GB88 binds towards the surface of the TM near to Tyr326 (7.35). However, the 11	  
exposure of the very hydrophobic spiroindenepiperidine to the solvent was 12	  
inappropriate, and GB88 can likely adopt alternative poses not evidently sampled in 13	  
the docking possibly because conformational flexibility of PAR2 was not a feature of 14	  
the model.  15	  
On closer investigation of the template from which the model was built, the 16	  
crystal structure of ORL-1 bound to antagonist C-24, led us to propose the possibility 17	  
of other potential binding poses adopted by GB88. First, the right side of 18	  
benzofuranpiperidine of C-24 is similar to the spiroindenepiperidine of the PAR2 19	  
ligand GB88. Since class A GPCRs often share a similar binding pocket and ligand 20	  
location, the binding of the benzofuranpiperidine in a deeper pocket created by M3.36 21	  
and Y1.56 in ORL-1 might possibly be mimicked by the spiroindenepiperidine 22	  
component of GB88 in PAR2. A more focused comparison between three residues of 23	  
PAR2 and ORL-1 might explain why the spiroindenepiperidine in the docked pose of 24	  
GB88 was not sampled in a similar pocket as queried. It was noticed that Asp3.32, 25	  
	   5	  
Val6.55 and Leu7.35 in ORL-1 are replaced by 3 larger residues: Phe3.32, Leu6.55 1	  
and Tyr7.35 in PAR2. As shown in Figure 2B, the superposition of the crystal 2	  
structure and homology model reveals a possible clash between the 3	  
spiroindenepiperidine and the blocking phenyl side chain from Phe155 (3.32) in 4	  
PAR2 during the molecular docking. 5	  
To explore other possible binding modes between PAR2 and GB88, a 30 ns MD 6	  
simulation was performed on PAR2 docked with GB88 in a simulated POPC 7	  
membrane environment. After MD simulations, a protein-ligand contact (Figure S1) 8	  
was generated using the simulation event analysis function (Desmond System v3.5, 9	  
D. E. Shaw Research, New York, NY, 2013). Results suggested that Tyr82 (1.39) 10	  
could still make a direct H-bond or water-mediated interaction with isoxazole. 11	  
Interestingly, another residue K131 (2.60), not predicted by docking, emerged as the 12	  
most frequent residue in contact with GB88 through direct hydrogen bonding with the 13	  
2nd and 3rd carbonyl oxygen of the ligand. Y1.39 has been reported as a well-14	  
conserved hotspot residue in other peptidergic GPCRs such as angiotensin and 15	  
chemokine receptors.23,24 In the CCR5 chemokine receptor structure25 and the recently 16	  
solved Angiotensin II receptor, antagonists interacted with Y1.39 via hydrogen 17	  
bonds.23 A similar protein-ligand interaction was also present in the opioid receptor 18	  
structure,22 in which Gln (2.60) formed a hydrogen bond to the antagonist. 	  19	  
Figure 2C shows the RMSD fluctuation of protein PAR2 and ligand GB88 20	  
throughout the simulation period. Stabilized by extensive protein-ligand interactions 21	  
shown in Figure S1, the small molecule antagonist GB88 was not observed to adopt 22	  
significant conformational changes compared to the protein, for which most flexibility 23	  
was observed for the residues located in the intracellular loops. The ligand 24	  
conformation was stable throughout the entire MD simulations, consistent with no 25	  
	   6	  
tendency for the hydrophobic group to re-locate into the alternative pocket mentioned 1	  
above. The snapshots from MD simulations provided a new source of receptor 2	  
conformations for further examination to explore other docking poses of GB88. 3	  
Ensemble docking following structure relaxation has proven to be effective in the 4	  
identification of several inhibitors for other proteins, which would not have been 5	  
possible by docking into the original crystal structure only.26,27 We integrated this 6	  
concept into the present study. From MD snapshots, we surmised that sampling 7	  
different structures of the receptor with different rotamers of F155 (3.32) might allow 8	  
the proposed pocket to open up and create more space to accommodate the bulky 9	  
spiroindenepiperidine of GB88. To test this hypothesis, structures of the receptor were 10	  
sampled at 15, 20, 25 and 30 ns in MD simulations, with the aid of visual inspection 11	  
for side-chain rotations of the above residues. Molecular docking of GB88 was 12	  
performed again based on these sampled structures. 13	  
Encouragingly, it was found that in one of the sampled structures after 30 ns MD 14	  
simulation, followed by docking of GB88 into the PAR2 structure, was the 15	  
hypothesized binding mode of the antagonist (Figure S2). Indeed, the movement of 16	  
the F3.32 side chain during MD simulations allowed the spiroindenepiperidine of 17	  
GB88 to insert into the hydrophobic cage created by Y3.33 and F6.48. In other 18	  
aminergic class A GPCRs, W6.48 was reported as a “toggle switch” residue that 19	  
played an important role during receptor activation. PAR2 has a Phe at this 20	  
topologically analogous position. The interaction between the spiroindenepiperidine 21	  
of GB88 with this residue may be key to the mechanism of its antagonism of PAR2.  22	  
The finding of this docked pose of GB88 suggests a new possible inactive 23	  
conformation of PAR2 for further ligand docking and modeling studies. Importantly, 24	  
the hydrophobic interaction between the spiroindenepiperidine and the receptor 25	  
	   7	  
aromatic cage residues (Y3.33, F6.48) may help differentiate biological profiles of 1	  
PAR2 ligands. This has been reflected to some extent by SAR studies from our group, 2	  
especially for small molecule potent agonists (unpublished), in which the C-terminal 3	  
amide of the ligand putatively binds at an upper position without penetrating through 4	  
the F155 mediated hydrophobic gate as compared to GB88 binding. The hydrophobic 5	  
nature of GB88 might allow it to avoid F155 and hence penetrate even deeper into the 6	  
pocket and, make hydrophobic interactions that lock the receptor in an inactive 7	  
conformation.  8	  
A similar phenomenon has been observed in a crystal structure for the class B 9	  
GPCR, the CRF receptor.28 In that structure, antagonist binding is restricted by side 10	  
chains of Phe 203 and Tyr 327 and for the ligand to reach the site it may require 11	  
rearrangement of residues at the top of the site through side-chain rotamer changes 12	  
and a shift of segments of TM3, TM5 and TM6, which then allows enlargement of the 13	  
putative ligand-binding site. To validate the potential use of the discovered binding 14	  
cavity adopted by GB88 as a novel site for prioritizing new PAR2 antagonists, we 15	  
applied virtual ligand screening by docking 1216 FDA-approved drugs from the 16	  
United States Environmental Protection Agency website 17	  
(http://www.epa.gov/ncct/dsstox/sdf_fdamdd.html). Current scoring functions are 18	  
generally capable of performing binding pose predictions from pose scoring, but are 19	  
still not very efficient for predicting binding affinity even after ligands are docked 20	  
into crystal structures of target proteins.29,30 Consequently, the success rate of a virtual 21	  
screening campaign also replies significantly on the experience and knowledge of the 22	  
operator working with protein-ligand interactions and visual inspection can play an 23	  
important role in determining the rate of success. The top ranking 150 drugs, as 24	  
judged by ChemPLP scores from GOLD software, were further visually inspected for 25	  
	   8	  
their docked poses and for interactions with residues in the putative binding site of 1	  
PAR2. Thus, docking scores were used here as a first filter, to eliminate compounds 2	  
unlikely to fit the putative docking site, and those with a relatively higher fitness score 3	  
were retained for detailed visual inspection as a focused sub-set of the compound 4	  
dataset. Finally, 8 drugs were selected for bioassays based on the ranking list derived 5	  
from virtual screening coupled with visual inspection of putative drug-receptor 6	  
interactions. 7	  
Given the simulations and in silico docking data, we measured the PAR2-binding 8	  
affinities of these 8 drugs (Figure S3) using CHO-hPAR2 cells and a competing 9	  
europium(III)-labeled 2f-LIGRLO-dpta-NH2 ligand for PAR2. Preliminary screening 10	  
showed that Pimozide, Carvedilol, Loratadine, Nefazodone and Astemizole bound 11	  
weakly to PAR2 at concentrations of 20-100 µM (Figure 3A). Concentration-12	  
dependent binding curves gave IC50 values of 46 µM, 28 µM, 39 µM, 24 µM and 16 13	  
µM respectively (Figure 3B).  14	  
Functional antagonism by these drugs was determined using calcium 15	  
mobilization, and 4 drugs (Carvedilol, Loratadine, Nefazodone, Astemizole) were 16	  
found to have ≥ 50% inhibition at 30 µM (Figure 4A). These compounds were chosen 17	  
for further concentration-response measurements, with IC50 = 14 µM, 55 µM, 10 µM 18	  
and 13 µM respectively (Figure 4B). Pimozide was not a PAR2 antagonist in the Ca2+ 19	  
release assay. To ensure that the antagonism of the four drugs was not due to their 20	  
agonist-induced desensitization of PAR2, the agonist activity of each drug alone was 21	  
also measured (Figure S4). The PAR2 ligands exhibited minimal agonist activity 22	  
(Figure S4). Together, the binding and Ca2+ mobilization results suggested that the 23	  
four drugs inhibited PAR2 activation via docking in a similar binding site as the 24	  
agonist 2f-LIGRLO-NH2 in PAR2. 25	  
	   9	  
Carvedilol, Loratadine, Nefazodone and Astemizole were also tested for 1	  
antagonism of PAR2-mediated ERK1/2 phosphorylation, a well-documented reporter 2	  
of a different GPCR signaling pathway that has been linked to cancer development 3	  
and inflammatory diseases.31 Consistent with the Ca2+ mobilization data, Carvedilol 4	  
(IC50 = 28 µM), Loratadine (IC50 = 27 µM), Nefazodone (IC50 = 44 µM) and 5	  
Astemizole (IC50 = 30 µM) all inhibited PAR2-mediated ERK1/2 phosphorylation 6	  
(Figure 4C) without detectable agonist properties. The finding of inhibition of 7	  
ERK1/2 phosphorylation by four PAR2 antagonists is noteworthy, since most PAR2 8	  
antagonists reportedly inhibit calcium mobilization but not ERK1/2 phosphorylation, 9	  
one exception32 being C391 which is an analogue of the agonist 2f-LIGRLO-NH2.  10	  
Since PAR2 is a mediator of inflammation and cancer,33,34 the four antagonists 11	  
were also investigated for inhibition of PAR2-mediated IL-6 secretion in human 12	  
MDA-MB-231 breast cancer cells. Both Loratadine and Carvedilol (30 µM) blocked 13	  
PAR2-mediated secretion of the inflammatory cytokine IL-6 in these cells (Figure 14	  
4D). IL-6 has been linked to inflammatory diseases and cancers35 and is involved in 15	  
the recruitment and activation of JNK and downstream activation of cell proliferation 16	  
and differentiation.36 In cancer, IL-6 decreases cancer cell apoptosis, promotes 17	  
angiogenesis and therapy resistance, and IL-6 serum levels correlate with the clinical 18	  
stage of breast cancer and prognosis.37 Loratadine and Carvedilol may be useful 19	  
scaffolds for building PAR2 antagonists into anticancer agents.  20	  
 To identify putative binding modes of the drugs in PAR2, molecular docking 21	  
with more GA runs (30 for each ligand) was performed in the binding site used for the 22	  
virtual screening. Docking simulations predicted binding sites of these drugs to be the 23	  
same as for GB88 (Figure 5). For Carvedilol (Figure 5A and S5A), the tricyclic 24	  
carbazole ring was sandwiched by Y82 and W127, the hydrogen atom on the ring 25	  
	   10	  
forms a hydrogen bond with the carbonyl oxygen of W127, the hydroxyl group forms 1	  
a putative hydrogen bond with K131, while the 2-methoxyphenoxy group docks 2	  
within the hydrophobic cleft mentioned above. Loratadine, being a smaller molecule 3	  
compared to the others, partially binds in the pocket occupied by the other drugs 4	  
(Figure 5B and S5B). The lack of interaction with the hydrophobic cleft residues may 5	  
explain its weaker activity compared to the other drugs. Nefazodone (Figure 5C and 6	  
S5C) and Astemizole (Figure 5D and S5D) adopted similar binding poses as 7	  
Carvedilol, interacting with similar residues in the same binding pocket. An 8	  
interesting observation is that all drug hits identified here originally targeted the 9	  
aminergic group of class A GPCRs (e.g. Carvedilol for β1 adrenoreceptor, Loratadine 10	  
and Astemizole for histamine H1-receptor, Nefazodone for 5HT1A).  Therefore, a 11	  
focused comparison of the ligand accessible binding site in PAR2 with these other 12	  
receptors was also performed using the GPCRDB web tool (http://tools.gpcr.org/).38 13	  
Figure S6 summarizes residue similarities and differences at the ligand-binding site of 14	  
these receptors. Hydrophobic residues dominated the binding site similarity among 15	  
the 4 GPCRs, whereas the major difference observed was for conserved polar residues 16	  
in the aminergic family (e.g. D3.32, T3.37, S5.42, S5.46 in β1 adrenoreceptor). Such 17	  
differences in the binding site prevent the drugs form forming key hydrogen bond 18	  
contacts with the hydrophobic residues at the corresponding conserved position in 19	  
PAR2 (e.g. F3.32, Y3.37, L5.42, V5.46 in PAR2). This is consistent with the 20	  
predicted interactions from docking, involving mainly hydrophobic interactions of the 21	  
drugs with the receptor, which resulted in only weak antagonism of PAR2. 22	  
Nonetheless, these hits, together with their predicted binding modes may help guide 23	  
further hit-to-lead development. 24	  
	   11	  
In conclusion, this research began by predicting a putative binding site for a 1	  
PAR2 antagonist (GB88) and then used this to conduct virtual screening of FDA-2	  
approved drugs for potential antagonism of PAR2. The predicted binding site, refined 3	  
by molecular dynamics simulations, resulted in a promising high hit rate in the virtual 4	  
screen. Computational simulations helped guide selection and optimization of the 5	  
protein conformation bound to a known antagonist, which in turn aided the 6	  
identification of the FDA-approved drugs (Nefazodone, Astemizole, Carvedilol, 7	  
Loratadine) as novel PAR2 antagonists (Table S1), the latter two inhibiting PAR2-8	  
mediated IL-6 secretion in MDA-MB-231 human breast cancer cells. This approach 9	  
to finding scaffolds for drug development might be useful in other cases where a 10	  
receptor crystal structure is similarly not available. MD simulations have gained in 11	  
popularity recently as part of the arsenal of computational tools developed to explore 12	  
the design of novel bioactive molecules and for investigating the mode of actions of 13	  
ligands on their protein targets.39 These findings have demonstrated the potential of 14	  
virtual screening of FDA-approved drugs to find novel hits that may be useful new 15	  
scaffolds for hit-to-lead development and repurposing against alternative drug targets. 	  16	  17	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Figures and Tables 1	  
 2	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Figure 2. Overlay of the PAR2 homology model with the crystal structure of the 8	  
template structure. (A) PAR2 homology model (violet) vs crystal structure of ORL-1 9	  
(green) (PDB code: 4EA3) bound to its antagonist C-24; (B) PAR2 homology model 10	  
(violet) with GB88 docked and crystal structure of ORL-1 (green); (C) RMSD plot of 11	  
protein (backbone) and ligand (heavy atoms) from MD simulations. 12	  
	   13	  
 1	  
Figure 3. Competitive PAR2 binding affinity of FDA-registered drugs vs known 2	  
agonist 2f-LIGRLO-dpta. (A) Ligand (3 concentrations) binding to CHO-hPAR2 3	  
cells. (B) Concentration-response curves for Pimozide, Carvedilol, Loratadine, 4	  
Nefazodone and Astemizole in PAR2 binding assay. Data shown are means ± SEM of 5	  
>3 independent experiments. 6	  
 7	  
 8	  
Figure 4. FDA-registered drugs are PAR2 antagonists. (A) Antagonism of calcium 9	  
mobilization in CHO-hPAR2 cells by FDA-approved drugs. (B) Concentration-10	  
dependent inhibition of PAR2-mediated calcium mobilization. (C) Concentration-11	  
dependent inhibition of PAR2-mediated ERK1/2 phosphorylation (D) Carvedilol or 12	  
loratadine (30 µM) inhibited PAR2-mediated IL-6 secretion from MDA-MB-231 13	  
human breast cancer cells. Data shown are means ± SEM of >3 independent 14	  
experiments. ***P < 0.001; significant differences as indicated. 15	  
	   14	  
 1	  
Figure 5. Molecular docking poses of four drugs within the PAR2 homology model 2	  
after 30 ns of molecular dynamics simulations. (A) Carvedilol (R-enantiomer docked 3	  
here), (B) Loratadine, (C) Nefazodone and (D) Astemizole. 4	  
 5	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Supporting Information Available: Protein-Ligand contacts plot between PAR2 and 3	  
GB88 throughout 30 ns MD simulations is shown in Figure S1. Re-docked pose of 4	  
GB88 into PAR2 homology model, the conformation sampled at 30 ns post-MD 5	  
simulations is illustrated in Figure S2. Structures of 8 FDA approved drugs are shown 6	  
in Figure S3. Agonist activity of 4 drugs in calcium mobilization in CHO-hPAR2 7	  
cells is shown in Figure S4. 2D protein-ligand interaction plots for the drug hits are 8	  
shown in Figure S5. Focused comparison at the ligand accessible binding site of 9	  
PAR2 against three class A GPCRs is shown in Figure S6. Table S1 summarizes FDA 10	  
approved drugs used in this study. All experimental details are described under 11	  
Methods in SI. This material is available free of charge via the Internet at 12	  
http://pubs.acs.org. 13	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